Initiate Phase 1 clinical trial of SER-252 in advanced Parkinson's disease patients
Delivered after the deadline (55 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 3 Feb 2025
- Due
- 31 Dec 2025
- Delivered
- 24 Feb 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“advancing SER-252 (POZ-apomorphine), enabled by its proprietary POZ Platform™ drug optimization technology, into a Phase 1 clinical trial in advanced Parkinson's disease patients in the second half of 2025”
What we found
Evidence strength B What the grades mean
Serina dosed the first patient in the SER-252 Phase 1b trial on Feb 24, 2026, after an FDA clinical hold delayed the original 2H 2025 target.
-
B Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 IND clearance came Jan 28, 2026, after the 2025 deadline
-
B Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 Confirms first patient dosed on Feb 24, 2026
-
D Serina Therapeutics FDA Clears SER-252 for Parkinson's Disease Describes Nov 2025 FDA clinical hold causing delay
-
D Serina Therapeutics (NYSE: SER) posts 2025 loss while funding SER-252 trials FY2025 filing confirms Feb 2026 first patient dosing
Checked 16 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Serina Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-SER-000114 · Corrections policy